Effect of APOCIII-L Rxon Lipoprotein Size and Particle Numbers Measured by NMR in Patients with Hypertriglyceridemia: Results of the AKCEA-APOCIII-L-Rx Trial

Ewa Karwatowska-Prokopczuk,Jean-Claude Tardif,Daniel Gaudet,Christie M. Ballantyne,Michael D. Shapiro,Patrick M. Moriarty,Seth J. Baum,Eric St Amour, Vickie Alexander,Shuting Xia,James D. Otvos,Joseph L. Witztum,Sotirios Tsimikas

Circulation（2021）

引用 0|浏览4

暂无评分

摘要

Background: APOCIII-LRx is a hepatocyte-targeted, GalNAc-modified antisense oligonucleotide that decreases plasma levels of apoC-III and triglyceride-rich lipoproteins (TRLs). We examined the effec...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要